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We conducted a phase II study to evaluate tolerability and efficacy of Clofarabine and 
Treosulfan as conditioning regimen prior to allogeneic hematopoietic stem cell 
transplantation (allo-HSCT). Primary objective was evaluation of the cumulative 
incidence of non-relapse mortality (NRM) on day +100. Forty-four patients (37 acute 
myeloid leukemias, 5 acute lymphoblastic leukemias, 3 myelodysplastic syndromes) 
were enrolled. Conditioning regimen was with Clofarabine 40 mg/m2 (day -6 to -2) and 
Treosulfan 14 g/m2 (day -6 to -4). Allogeneic haematopoietic stem cells were derived 
from a sibling (n=23) or a well-matched unrelated donor (n=21). Graft versus host 
disease (GvHD) prophylaxis consisted of Thymoglobuline, Rituximab, Cyclosporine 
and short course Methotrexate. The regimen allowed rapid engraftment and was well 
tolerated with a 2-year transplant related mortality of 18%. Cumulative incidences of 
grade 2-4 acute and chronic GvHD were 16% and 19% respectively. 2-year overall 
survival (OS), progression free survival and relapse incidence were 51%, 31% and 50% 
respectively. A significant difference emerged between patients with 
“low/intermediate” vs “high/very high” disease risk index (1-year OS 78% and 24%). 
Treosulfan and Clofarabine combination is feasible, safe and allows prompt 
engraftment. The considerable relapse incidence in patients with poor prognostic risk 







Allogeneic hematopoietic stem cell transplantation (HSCT) can be curative for patients 
with hematological malignancies. The ideal conditioning regimen before allogeneic 
HSCT has not yet been established. Reduced-intensity conditioning (RIC) regimens 
emerged more than 15 years ago with the aim of decreasing the toxicity and morbidity 
related to HSCT. Unfortunately, the trade-off for RIC has been an increase in disease 
recurrence and a high incidence of chronic graft-versus-host disease (cGvHD) with its 
considerable impact on late transplantation-related mortality (TRM) and quality of life. 
Progressively, the concept of RIC switched to the concept of reduced-toxicity 
conditioning (RTC), based on the combination of Fludarabine and an alkylating agent, 
which currently represent the back-bone in conditioning regimens for HSCT performed 
world-wide.  
Treosulfan is a water-soluble bi-functional alkylating cytotoxic agent often considered 
as an alternative agent to Busulfan in conditioning regimens because of its well-known 
advantages, such as low non-hematologic toxicity profile, broad stem cell toxicity, and 
immunosuppressive as well as anti-leukemic activity. In the last decade, the 
combination of Treosulfan and Fludarabine proved to be feasible and efficient in 
several types of malignancies, including acute myeloid leukemia (AML) and 
myelodysplastic syndromes(1-3).  
Clofarabine is a second-generation purine nucleoside analogue; it requires intracellular 
phosphorylation to be activated and is resistant to deamination. In addition to inhibiting 
DNA polymerase, Clofarabine also acts as an inhibitor of cellular ribonucleotide 
reductase. It has been documented that Clofarabine has significant anti-leukemic 
activity, particularly in relapsed acute lymphoblastic leukemia (ALL), and the drug is 
approved for the treatment of pediatric ALL patients after at least two prior regimens. 
Clofarabine was also studied in relapsed AML. Direct induction of apoptosis by 
activation of caspase 9 and direct interaction with the mitochondrial membrane may 
also play a role in this superior anti-leukemic effect. Hand-foot syndrome and reversible 
liver function abnormalities are the two main adverse events of the drug described in 
the literature (4).  
With the aim of identifying a better RTC regimen, both in terms of efficacy and 
tolerability, we investigated a novel combination of drugs and here we present the 
results of a prospective, multicenter phase II trial (“Clotreo”, EudraCT 2008-006972-
31), testing the use of a conditioning regimen with Clofarabine replacing Fludarabine, 
in combination with Treosulfan and antithymocyte globulin (Thymoglobuline), in 44 
patients affected by acute leukemia or high-risk myelodysplastic syndrome. 
 
MATERIALS AND METHODS 
 
Patients and Donors 
This prospective phase II study was conducted at five bone marrow transplant centers 
in Italy (Milan, Udine, Torino, Bolzano and Pavia). The study was approved by the 
institutional review board of each participating center. Patients had to be between 1 and 
70 years of age, with an available human leukocyte antigen (HLA) matched related or 
unrelated donor. HLA-compatibility among donor-recipient pairs was assessed by ten 
loci molecular typing (HLA-A,-B,-C,-DRB1,-DQB1), with no more than a two allele 
disparity allowed. 
Additional eligibility criteria included creatinine clearance above 50 ml/min, alanine 
aminotransferase ≤ 2.5 times the upper normal limit, a Karnofsky performance status  
80%, an hematopoietic cell transplantation-comorbidity index (HCT-CI) according to 
Sorror of less than 4(5). Patients with a previous HSCT were excluded. From November 
2009 to November 2013, we enrolled 44 patients (median age 47 years), 36 affected by 
acute myeloid leukemia, 5 by acute lymphoblastic leukemia and 3 by myelodisplastic 
syndrome. Comorbidities at time of transplantation were evaluated according to HCT-
CI. Patients were stratified by disease type and status at the time of transplantation, 
according to the disease risk index (DRI) validated by Armand and collaborators (6). 
27 patients belonged to the “low-intermediate” group, while 17 were at “high-very 
high” risk. Patient, disease and transplantation characteristics are summarized in Table 
1.  
 
Conditioning Regimen and GvHD Prophylaxis 
All patients received Treosulfan 14 g/m2 for 3 days (day -6 through -4) and Clofarabine 
40 mg/m2 for 5 days (day -6 through -2). 
GvHD prophylaxis consisted of in vivo T cell-depletion by Thymoglobuline for 3 days 
(day -4 through -2) at two different dosages according to HLA matching: 1.5 mg/kg/day 
for patients with a 10/10 donor, 2.5 mg/kg/day for patient-donor pairs with any 
mismatch. All patients received a single dose of Rituximab at 200 mg/m2 on day -1 for 
in vivo B cell-depletion; Cyclosporine from day -1 (target plasmatic levels between 150 
and 250 ng/ml) and short-course Methotrexate (15 mg/m2 on day +1, 10 mg/m2 on day 
+3 and +6) with folinic rescue were additionally used for GvHD prophylaxis.  
In the absence of GvHD or disease relapse Cyclosporine was tapered to discontinuation, 
starting at month +3 after HSCT in patients with a “high-very high” DRI, and at month 
+6 in patients with “low-intermediate” DRI, with the aim of maximally exploiting the 
graft versus leukemia effect exerted by the donor’s immune system, selectively in those 
patients with the highest probability of disease recurrence. 
 
Donor Graft 
Peripheral blood stem cells were obtained from donors using standard mobilization 
protocols and apheresis techniques. A median of 6.0x106 CD34pos/kg (range 1.3-14.4) 
were infused. If peripheral blood mobilization was not possible and in all pediatric 
patients, bone marrow (BM) was the stem cell source instead.  
 
Supportive Care 
Microbial, fungal and viral prevention, together with the treatment of infectious 
complications were performed according to institutional transplant guidelines, 
following international recommendations(7) (8) (9). Allogeneic recipients have been 
screened for the presence of CMV in peripheral blood samples 1 time/week from HSCT 
to at least 100 days after HSCT. Diagnostic tests to determine the need for preemptive 
treatment included the detection of CMV DNA by quantitative polymerase chain 
reaction (PCR). Ganciclovir was used first-line for preemptive treatment of CMV. For 
prevention of EBV-related post transplant lymphoproliferative disease, patients were 
monitored every two weeks for EBV DNA load using a blood EBV PCR assay. Testing 
for galactomannan in serum was performed every week, by adopting PCR-based 
diagnostics. 
Acute GvHD was graded according to the consensus criteria(10) and cGvHD was 
classified according to the NIH criteria  (11). GvHD was treated as per institutional 
protocols, considering the EBMT-ELN recommendations(12). 
 
Evaluation of response 
Neutrophil engraftment was defined as neutrophil counts ≥ 0.5x109/L for more than 
three consecutive days; platelet engraftment was defined as platelet counts ≥ 20x109/L 
for more than three consecutive days in the absence of transfusions. Toxicity after 
HSCT was graded according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE v.3). Post-transplantation disease follow-up 
comprised monthly marrow evaluations for the first three months after HSCT, and 
thereafter every three months for the first year. Response and relapse were determined 
by standard hematological criteria. Hematopoietic chimerism was assessed on BM 
aspirate samples by performing in parallel short-tandem repeats.  
 
Statistical analysis 
Categorical variables are expressed as proportions, and continuous variables are 
expressed as the median with the respective range. Comparisons between groups were 
performed with the chi-square and Mann-Whitney tests for categorical and continuous 
variables, respectively. Outcomes were calculated from the date of transplantation. 
Progression-free survival (PFS) was defined as the probability of being alive and 
progression-free at any time; non-relapse mortality (NRM) was defined as death 
without evidence of disease progression or relapse. Disease progression or relapse was 
treated as a competing event in the NRM analyses. The incidence of acute (aGvHD) 
and chronic cGvHD (cGvHD) was estimated considering disease progression or relapse 
as competing events. Only patients alive at day +100 after transplant were evaluated 
for cGvHD. Cumulative incidence of engraftment was calculated using death before 
engraftment as a competing event. The Kaplan-Meier method was used for survival 
analyses, hazard ratios were estimated with their respective 95% confidence intervals 
(CIs). The cumulative incidence method with competing risk was used for the NRM, 
relapse/progression, GvHD and engraftment analyses. P values ≤ .05 were considered 
significant. The statistical software packages SPSS version 16.0 (SPSS Inc., Chicago, 





Engraftment and chimerism 
93% of the patients achieved primary engraftment, with a median time for neutrophil 
recovery of 14 (range, 10-27) days, while that for platelet recovery was 12 (range, 7-
117) days. The median time for the platelet count to reach 50x109/L was 16 (range, 11-
156) days. A total of 3 patients died before neutrophil recovery. One patient 
experienced secondary graft failure two months after HSCT, concomitant to a severe 
invasive fungal infection: he was rescued by a BM-derived stem cells boost from the 
original donor. The patient is currently alive, in good clinical condition, in complete 
remission, and with normal peripheral blood counts. 
Full donor chimerism (> 95% donor chimerism) was documented in 100% of assessed 
patients at day +30 and confirmed at the following evaluations in patients maintaining 
a complete disease remission.  
 
Toxicity 
Table 2 summarizes all adverse events observed during conditioning and after HSCT 
graded > 2. Overall, reversible hepatic damage and body weight gain were the most 
frequent side effects, the latter occurring in 14/44 subjects (32%), mainly due to liquid 
retention and thus usually managed with maximal diuretic stimulation. Skin rash after 
Clofarabine administration was frequently observed, but was reversible and of low 
severity in the vast majority of cases (only 3 patients presented severe cutaneous 
lesions). Five patients experienced an increase in creatinine levels, with a maximal 
severity grade of 2.  
With regard to infectious events, febrile neutropenia occurred in > 70% of patients, 8 
subjects suffered from septic shock, which was ultimately fatal in 7 patients. 
Pneumonitis was diagnosed in five patients, being the cause of death in one case only. 
One patient was diagnosed with a proven fungal pneumonia that was successfully 
treated with a surgical lobectomy. Seven patients experienced EBV reactivation, but 
only two of them required treatment and no EBV related lymphoma occurred. 
Reactivation of cytomegalovirus occurred in 23 patients (52%), with a median time of 
onset of 28 days (range 6-52) from transplantation. 
Finally, one patient died during the conditioning regimen because of massive cerebral 
hemorrhage.  
Other adverse events were infrequent and of lower severity (see Table 2). 
Overall, the 1-year NRM incidence was 18 (95% CI: 7-30) (Figure 1).  
 
Acute and chronic graft-versus-host disease 
Grades 2, 3 and 4 acute GvHD occurred in one, four and one patient respectively. The 
cumulative incidence of grades 2–4 acute GvHD was 16% (95% CI: 4-28), while the 
cumulative incidence of grades 3–4 acute GvHD was 13% (95% CI: 2-24). The median 
time of diagnosis was at 54 days post transplant (range 11-111). The cumulative 
incidence of chronic GvHD (all grades) was 19% (95% CI: 5-33). Overall, 7 patients 




With a median follow-up of 27 (range, 0-61) months after allogeneic HSCT, the 1-year 
overall survival (OS), progression-free survival (PFS) and relapse incidence were 60% 
(95% CI: 52-68), 41% (95% CI: 34-48) and 41% (95% CI: 26-56), respectively. The 
corresponding figures at 2 years were 51% (95% CI: 43-59), 31% (95% CI: 24-39) and 
50% (95% CI: 34-67) respectively (Figure 2A). At 1 year, 18 patients had relapsed 
(41%) within a median time of 3.4 (range, 1–9.5) months after transplantation. Three 
additional relapses occurred at 12.5, 20.6 and 20.9 months.  
As expected, patients belonging to the ‘high-very high’ DRI group displayed 
significantly lower OS and PFS rates, as compared with those with a ‘low-intermediate’ 
DRI: 24% (95% CI: 11-37) versus 78% (95% CI: 70-86) and 9% (95% CI: 1-17) versus 
59% (95% CI: 50-69), respectively at 1 year (p<0.0001; Figure 2B), and this was 
consistently related to a higher relapse rate in patients affected by advanced diseases: 
68% (95% CI: 41-95) versus 26% (95% CI: 9-43); p=0.002; Figure 3C.    
Five patients with overt disease relapse received either a single (n=2) or two (n=3) 
donor lymphocyte infusions, with a documented response in only one of them. Five 





In an era in which allogeneic HSCT is considered the potential curative treatment not 
only for the majority of hematological malignancies, but also for other non-malignant 
diseases, such as genetic or autoimmune disorders, there is a continuous search for 
novel conditioning regimens that will reduce HSCT-related toxicity while retaining 
maximal anti-malignancy effect. Although advances in transplantation approaches over 
the past few decades have led to markedly improved outcomes after allogeneic HSCT, 
the mortality due to disease recurrence remained largely unchanged(13). However, 
approaches for reducing relapse, such as more intensive conditioning regimens, could 
also increase toxicities without improving overall outcomes(14).  
The combination of Fludarabine with an alkylating agent has become more and more 
popular in the last decade; the available safety and efficacy data favor such a 
combination over that of double alkylating agent regimens such as Busulfan-
Cyclophosphamide(15).  
Treosulfan is a new generation alkylating agent with a myeloablative effect on 
committed and non-committed stem cells, as extensively investigated in preclinical 
studies. Moreover, it has potent immunosuppressive activity, which makes it an 
attractive candidate for its use in conditioning regimens before allo-HSCT, as compared 
to Busulfan. Of note, Treosulfan toxicity profile is favorable thanks to its limited 
extramedullary toxicity.  
The combination of Fludarabine and Treosulfan was explored in patients not eligible 
for standard myeloablative conditioning, and data are rapidly emerging. This regimen 
is associated with consistent engraftment and favorable survival in the range of 40-
80%. Promising results were seen in myelodysplastic syndrome and leukemia in 
remission. 
While Fludarabine primarily acts as an immunosuppressant, the more recently 
synthetized purine nucleoside analog Clofarabine has demonstrated higher anti-
leukemic activity. Clinical trials using Clofarabine within the conditioning regimen 
prior to allo-HSCT allowed elucidation of its role in terms of anti-leukemic potential, 
immunosuppressive and engrafting-promoting activity. The first published trial using 
Clofarabine (in association with Cytarabine) in transplant conditioning reported an 
unacceptably high rate of poor donor chimerism(16).  
Here, we report results of a multicenter trial (‘Clo3o’, EudraCT 2008-006972-31) 
investigating a new conditioning regimen based on Clofarabine substituting 
Fludarabine. In our study Clofarabine was combined with Treosulfan and both 
engraftment and chimerism data were encouraging. Recently, other authors reported 
good engraftment even with Clofarabine and Busulfan based conditioning, inferring 
that the immunosuppressant potential of Clofarabine is enough to guarantee 
engraftment and full donor chimerism(17)  (18-20). From literature data, Clofarabine-
based conditioning regimens display a NRM ranging from 26% to 32% at 1 year. Of 
note, all studies included either Busulfan or Melphalan in the conditioning schedule(21)  
(22)  (23). In our study, Clofarabine and Treosulfan allowed a favorable toxicity profile, 
with a 1-year NRM of 18%.  
By incorporating Clofarabine in the conditioning regimen our main aim was to improve 
disease control and reduce relapse incidence but we observed opposing results. While 
patients belonging to the ‘low-intermediate’ DRI group experienced an encouraging 
59% of PFS at 1 year, with a 79% OS, subjects with a ‘high-very high’ DRI displayed 
9% of PFS with 24% OS at 1 year. All patients treated in our trial, regardless of HLA 
matching, received in vivo T and B-cell depletion, by Thymoglobulin and Rituximab 
respectively, besides Cyclosporine and short course Methotrexate. The dose of 
Thymoglobulin was adjusted according to HLA disparity. This robust 
immunosuppressive regimen resulted in promising (even lower than expected) acute 
and chronic GvHD incidence. Indeed, in vivo T-cell depletion has been recently shown 
to lower the incidence of chronic GvHD among patients in complete remission from 
acute leukemia who received peripheral blood stem cells from an HLA-identical 
sibling(24). However, we speculate that the disappointing high relapse rate observed in 
patients with advanced disease in our experience could be at least partially explained 
by our GvHD prophylaxis policy. Accordingly, to reduce the relapse incidence, high-
risk patients may benefit from a less aggressive GvHD prophylaxis, namely a 
modulation of in vivo T-cell depletion, especially when receiving a graft from an HLA-
fully matched sibling donor.  
To our knowledge, this is the first study combining Clofarabine and Treosulfan as 
conditioning prior to allogeneic HSCT and has demonstrated a favorable toxicity 
profile. The considerable relapse incidence in patients with poor prognostic risk factors 
is still a major issue. 
Still, options for decreasing the risk of disease relapse are limited thus far, with little 
chance of further implementing the efficacy and safety profiles of current conditioning 
regimens. Given these limitations, prophylactic or pre-emptive post HSCT strategies 
targeting minimal residual disease will play a dominant role in future clinical trials.  
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Figures and tables 
Table 1. Patients, disease and transplant characteristics 
  All transplants MRD transplants MUD transplants  
  Total number  44  22  22   
   
Patient characteristics 
      
 Median age at HSCT, years (range) 47 (13-69) 43 (13-61) 50  (16-69)  
 Male sex, n (%) 22 (50%) 9 (41%) 13 (59%)  
  
Disease diagnosis, n (%) 
       
 Acute myeloid leukaemia 36 (82%) 17 (77%) 19 (86%)  
 Myelodisplastic syndrome 3 (7%) 3 (14%) 0   
 Acute lymphoblastic leukaemia 5 (11%) 2 (9%) 3 (14%)  
   
Status at transplant, n (%) 
      
 First complete remission 16 (36%) 8 (36%) 8 (36%)  
 Other complete remission 9 (20%) 4 (18%) 5 (23%)  
 Active disease 16 (36%) 7 (32%) 9 (41%)  
 Upfront 3  (8%) 3 (14%) 0   
  
Comorbidities (HCT-CI) § , n (%) 
       
 0 15 (34%) 10 (45%) 5 (23%)  
 1-2 12 (27%) 5 (23%) 7 (32%)  
 3-4 17 (39%) 7 (32%) 10 (45%)  
   
Disease Risk Index (DRI) ¶, n (%) 
      
 Low 1 (2%) 1 (4%) 0   
 Intermediate 26 (59%) 14 (64%) 12 (55%)  
 High 13 (30%) 5 (23%) 8 (36%)  
 Very High 4 (9%) 2 (9%) 2 (9%)  
  
 CMV serostatus (host/donor) , n  
      
 
 negative/negative 2  0 2   
 negative/positive 2  1  1   
 positive/negative 11  3  8   
 positive/positive 29  18  11   
   
Donor-recipient HLA matching, n (%)‡ 
       
 MRD      
 (10/10) - - 22 (100%) - -  
  MUD        
 (8/10) - - - - 1 (4%)  
  (9/10) - - - - 7 (32%)  
 (10/10) - - - - 14 (64%)  
       
MRD: matched related donor; MUD: matched unrelated donor; HSCT: haemopoietic 
stem cell transplantation; GvHD: graft-versus-host disease; HLA: human leukocyte 
antigen; DRI: Disease Risk Index; HTC-CI: Comorbidity Index; CMV: 
cytomegalovirus. ‡Donor-recipient HLA matching: at 4-digit for 5 HLA loci (HLA-A, 
-B, -C, -DRB1, -DQB1). ¶ Disease Risk Index (DRI) according to Armand and 
collaborators. § Comorbidities at time of transplantation were evaluated according to 
the Comorbidity-Index by Sorror et al. 
 
 
Table 2. Toxicities  
 
 




      
 
   Febrile neutropenia 
    
   Liver enzymes   
 
   Septic shock 
 
   Mucositis 
 
   Pneumonia 
 
   Skin lesions§ 
 
   CNS infection 
 
   Hematuria/cystitis 
 
   Nausea 
 
   Pleural effusion 
 
   VOD 
 
   DVT 
 
   Arrhythmia 
 
   CNS bleeding 
 
   Microangiopathy 
 


































































     
 
§ Rash, erytrodermia, ulcerations; CNS: central nervous system; VOD: veno occlusive 














































RI, DRI low/intermediate 
RI, DRI high/very high 
months from transplantation 
months from transplantation 
